On September 19, the CDC released new pneumococcal vaccination recommendations for the adult population. Adults 65 years of age or older are now recommended to receive a single pneumococcal conjugate vaccine (PCV13, Prevnar-13®), followed by the pneumococcal polysaccharide vaccine (PPSV23, Pneumovax®23) 6-12 months later. For adults who previously received a dose of PPSV23 on or after turning 65 years of age, the PCV13 is recommended to be administered at least 1 year after the PPSV23.
The following are links to resources regarding pneumococcal vaccination recommendations.